A Phase 1/2 interventional study of Palifermin in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome, sponsored by Brett King. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-30.
Sponsored by Brett King · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Stevens-Johnson Syndrome with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Stevens-Johnson Syndrome · United States.
Among the 11 studies in Stevens-Johnson Syndrome with a site in United States, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2010, is one of 5 in phase 1/2, and was the 4th registered.
40 studies on the registry are indexed under Stevens-Johnson Syndrome; 8 are open to participants now.
Browse Stevens-Johnson Syndrome studies →1 of the 11 studies in Stevens-Johnson Syndrome with a site in United States is open now. Recruiting first, the newest first:
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Stevens-Johnson Syndrome studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 2
First in 2005; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 20 across 24 interventional studies indexed under Stevens-Johnson Syndrome.
Median enrollment 1 across the 10 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 9 most frequent:
Brett King is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Brett King has 1 study filed under Stevens-Johnson Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Stevens-Johnson Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06926478Massachusetts Eye and Ear InfirmarySubconjunctival Humira for Boston Keratoprosthesis | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Stevens-Johnson Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Palifermin 60 micrograms/kg/day IV for 3 consecutive days
Drug: Palifermin
Also known as: Kepivance
Time-to-cutaneous Re-epithelialization
Time frame: The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days
Time-to-mucosal Re-epithelialization
Time frame: The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days
Time-to-cessation of Epidermal Necrosis
Time frame: The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days
| Milestone | Palifermin |
|---|---|
| Started | 1 |
| Completed | 1 |
| Not completed | 0 |
| days | Palifermin |
|---|---|
| Time-to-cutaneous Re-epithelialization | 6 |
No measurements were reported for this outcome.
| days | Palifermin |
|---|---|
| Time-to-cessation of Epidermal Necrosis | 3 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palifermin | — | 1/1 (100%) | 0/1 (0%) |
| Event | Palifermin |
|---|---|
| ischemic necrosisGastrointestinal disorders | 1/1 |
73-year-old male.
| Age, Customized(years) | Palifermin |
|---|---|
| Age | 73 |
| Sex/Gender, Customized(participants) | Palifermin |
|---|---|
| Male | 1 |
The record gives a start of Oct 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fibroblast Growth Factor 7
Brett King